Niketa C Shah, MD
Associate Professor AdjunctDownloadHi-Res Photo
Cards
Appointments
Additional Titles
Director,Pediatric Cellular Therapy Program, Pediatric Hematology & Oncology
Director, Pediatric Bone Marrow Transplant Program
Contact Info
Pediatric Hematology & Oncology
333 Cedar Street, LMP 2073
New Haven, CT 06510
United States
Appointments
Additional Titles
Director,Pediatric Cellular Therapy Program, Pediatric Hematology & Oncology
Director, Pediatric Bone Marrow Transplant Program
Contact Info
Pediatric Hematology & Oncology
333 Cedar Street, LMP 2073
New Haven, CT 06510
United States
Appointments
Additional Titles
Director,Pediatric Cellular Therapy Program, Pediatric Hematology & Oncology
Director, Pediatric Bone Marrow Transplant Program
Contact Info
Pediatric Hematology & Oncology
333 Cedar Street, LMP 2073
New Haven, CT 06510
United States
About
Titles
Associate Professor Adjunct
Director,Pediatric Cellular Therapy Program, Pediatric Hematology & Oncology; Director, Pediatric Bone Marrow Transplant Program
Appointments
Pediatric Hematology & Oncology
Associate Professor AdjunctPrimary
Other Departments & Organizations
- Pediatric Bone Marrow Transplant Program
- Pediatric Hematology & Oncology
- Pediatric Hematology & Oncology Program
- Pediatrics
- Yale Cancer Center
Education & Training
- Pediatric Stem Cell Transplant Fellow
- Memorial Sloan Kettering Cancer Center (2010)
- Pediatric Resident
- Newark Beth Israel Medical Center (2009)
- Pediatric Hematology Oncology Fellow
- The Hospital For Sick Children, Toronto (2006)
- MD
- Seth K M School of Postgraduate Medicine and Research, Pediatrics (1997)
- MBBS
- NHL Municipal Medical College (1994)
Research
Overview
Medical Research Interests
Anemia, Sickle Cell; Bone Marrow Failure Disorders; Bone Marrow Transplantation; Hematology; Hematopoietic Stem Cell Transplantation; Pediatrics; Receptors, Chimeric Antigen
Research at a Glance
Yale Co-Authors
Frequent collaborators of Niketa C Shah's published research.
Publications Timeline
A big-picture view of Niketa C Shah's research output by year.
Research Interests
Research topics Niketa C Shah is interested in exploring.
Aron Flagg, MD
Lakshmanan Krishnamurti, MD
Farzana Pashankar, MD, MRCP, MBBS
Jingchen Liang
Lohith Gowda, MD, MRCP
Pramod Bonde, MD, FACS
51Publications
185Citations
Hematopoietic Stem Cell Transplantation
Anemia, Sickle Cell
Bone Marrow Transplantation
Receptors, Chimeric Antigen
Publications
2025
Donor, Recipient, and Parent Characteristics Associated with Poor Pediatric Sibling Hematopoietic Stem Cell Donor Pre-Donation Health-Related Quality-of-Life; Early Results of the Donorkids QL Study
Switzer G, Bruce J, Shaw B, Kuniyil V, Varni J, Butler B, Erickson C, Mussetter A, Aguayo-Hiraldo P, Anderson E, Aquino V, Boone K, Chewning J, Dahlberg A, Dvorak C, Haight A, Hoag J, Hudspeth M, Jacobsohn D, Kasow K, Kitko C, Miller H, Olson T, Pawlowska A, Prasad V, Quigg T, Scaradavou A, Shah N, Shenoy S, Silva J, Terwilliger N, Wiener L, Yanik G, Yu L, Pulsipher M. Donor, Recipient, and Parent Characteristics Associated with Poor Pediatric Sibling Hematopoietic Stem Cell Donor Pre-Donation Health-Related Quality-of-Life; Early Results of the Donorkids QL Study. Transplantation And Cellular Therapy 2025, 31: s95-s96. DOI: 10.1016/j.jtct.2025.01.151.Peer-Reviewed Original ResearchAltmetricConceptsHealth-related quality-of-lifeQuality-of-lifePoorer health-related quality-of-lifeFamily unitFamily cohesionPredictors of HRQoL.Aged 5Low parental education levelSelf-reported depressionParental demographic characteristicsParental education levelDonation processParental HRQoLPsychosocial scoresPartnership statusLow family cohesionQL studiesFamily characteristicsPsychosocial effectsHRQoLEmployment statusEducation levelHRQoL.Pre-donationInterview data
2024
Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease
Krishnamurti L, Liang J, He Z, Deng Y, Nallagatla V, Hamidi R, Flagg A, Shah N. Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease. Blood Advances 2024, 8: 1908-1919. PMID: 38324722, PMCID: PMC11021890, DOI: 10.1182/bloodadvances.2023010749.Peer-Reviewed Original ResearchCitationsAltmetricConceptsHematopoietic cell transplantationSickle cell diseaseVaso-occlusive episodesPainful crisesCell transplantationPost-HCTGraft failureBefore HCTEvent-free survivalOverall survivalPain syndromePatient agePatient-centered outcomesAlternative donorsIncreased riskCell diseaseRisk factorsNatural historyPatientsLogistic regressionPainTransplantationSurvivalAgeAGVHDImpact of CMV Reactivation on Clinical Outcomes Post Allogeneic Stem Cell Transplant in Patients with Sickle Cell Disease
Rahim M, Ngwube A, Shenkar R, Rohaum H, Rao A, Stanek J, Shah N, Rangarajan H. Impact of CMV Reactivation on Clinical Outcomes Post Allogeneic Stem Cell Transplant in Patients with Sickle Cell Disease. Transplantation And Cellular Therapy 2024, 30: s302. DOI: 10.1016/j.jtct.2023.12.413.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationImpact of CMV reactivationReduced intensity conditioningSickle cell disease patientsAllogeneic hematopoietic stem cell transplantationSickle cell diseaseStem cell transplantationCMV reactivationMixed chimerismCell transplantationGraft failurePost-allogeneic hematopoietic stem cell transplantationRecovery of absolute lymphocyte countPost allogeneic stem cell transplantationAbsence of CMV-reactivationAllogeneic stem cell transplantationRabbit anti-thymocyte globulinMulti-institutional retrospective studyWhole bloodRisk of graft failureIncidence of GFPre-engraftment periodAnti-thymocyte globulinAbsolute lymphocyte countCompare clinical outcomes
2023
Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders
Ngwube A, Shah N, Schulz G, Krishnamurti L, Shenoy S. Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders. Blood 2023, 142: 4901. DOI: 10.1182/blood-2023-191145.Peer-Reviewed Original ResearchConceptsNon-malignant disordersPost-transplant cyclophosphamideSickle cell diseaseGVHD prophylaxisHematopoietic transplantationEvaluable patientsHaploidentical transplantationImmune suppressionBone marrowFirst year post-HCTGrade 1 acute GVHDChronic GVHD riskChronic skin GVHDGVHD-free survivalPost-transplant lymphoproliferationsRadiation-containing regimensYear post-HCTPhase 2 trialReduced intensity conditioningSerious infectious complicationsSystemic immune suppressionT-cell chimerismAllogeneic hematopoietic transplantationPrimary outcome measureStem cell boostOutcomes after RIC and Abatacept-Based Acute and Chronic Gvhd Prophylaxis in Allogeneic Transplantation for Sickle Cell Disease - Can Calcineurin Inhibitor Use be Curtailed?
Shah N, Ngwube A, Jacobsohn D, Shenoy S. Outcomes after RIC and Abatacept-Based Acute and Chronic Gvhd Prophylaxis in Allogeneic Transplantation for Sickle Cell Disease - Can Calcineurin Inhibitor Use be Curtailed? Blood 2023, 142: 2185. DOI: 10.1182/blood-2023-190524.Peer-Reviewed Original ResearchConceptsDisease-free survivalSickle cell diseaseSevere sickle cell diseaseUnrelated donor transplantsGVHD prophylaxisAllogeneic transplantationCell diseaseChronic GVHDDonor transplantsMarrow transplantationGrade 2Unrelated donor stem cell transplantationAllogeneic T cell proliferationDonor stem cell transplantationUnrelated donor marrow transplantationCalcineurin inhibitor useHost disease (GVHD) prophylaxisRelated donor transplantsSevere chronic GVHDSuccessful allogeneic transplantationGroup 1 patientsPhase II trialImmune suppression therapyStem cell transplantationHuman leucocyte antigenCongenital Dyserythropoietic Anemia Type II: An Update from the Congenital Dyseryhtropoietic Anemia Registry of North America (CDAR)
Elgammal Y, Risinger M, Husami A, Walden J, Gupta S, Shah N, Boyer J, Abajas Y, Winstead M, Miller D, Vidal-Anaya V, Vlachos A, Lal A, Ritchey A, Lorsbach R, Zhang W, Kalfa T, Niss O. Congenital Dyserythropoietic Anemia Type II: An Update from the Congenital Dyseryhtropoietic Anemia Registry of North America (CDAR). Blood 2023, 142: 1079. DOI: 10.1182/blood-2023-189389.Peer-Reviewed Original ResearchConceptsIron overloadIneffective erythropoiesisCongenital dyserythropoietic anemiaBlood transfusionHepatic hemosiderosisHemolytic anemiaIron levelsFrequency of transfusionGDF-15 levelsWhole-genome sequencingSeverity of anemiaAge of diagnosisCDA IINatural history studiesBody iron levelsDeep intronic variantsCDA II patientsCDA type IIIntronic variantsAutosomal recessive diseaseBone marrow erythroblastsBM examinationFerritin ratioGDF-15Anemia severityMediport use as an acceptable standard for CAR T cell infusion
Eylon M, Prabhu S, John S, King M, Bhatt D, Curran K, Erickson C, Karras N, Phillips C, Satwani P, Hermiston M, Southworth E, Baumeister S, Talano J, MacMillan M, Rossoff J, Bonifant C, Myers G, Rouce R, Toner K, Driscoll T, Katsanis E, Salzberg D, Schiff D, De Oliveira S, Capitini C, Pacenta H, Pfeiffer T, Shah N, Huynh V, Skiles J, Fraint E, McNerney K, Quigg T, Krueger J, Ligon J, Fabrizio V, Baggott C, Laetsch T, Schultz L. Mediport use as an acceptable standard for CAR T cell infusion. Frontiers In Immunology 2023, 14: 1239132. PMID: 37965315, PMCID: PMC10642031, DOI: 10.3389/fimmu.2023.1239132.Peer-Reviewed Original ResearchAltmetricConceptsCAR T-cell infusionT-cell infusionCell infusionT-cell therapyCell infiltrationClinical practiceChimeric antigen receptor T-cell therapyCAR T-cell therapyCAR-T cell infiltrationCell therapyCell therapy administrationRetrospective cohort studyCentral venous cathetersT cell infiltrationCurrent clinical practiceStandard clinical practiceB-cell malignanciesT cell deliveryEvaluable patientsVenous optionsCohort studyVenous cathetersTherapy administrationPractice patternsCare recommendationsMixed donor chimerism following stem cell transplantation for sickle cell disease
Shah N, Rangarajan H, Ngwube A, Shenoy S. Mixed donor chimerism following stem cell transplantation for sickle cell disease. Current Opinion In Hematology 2023, 30: 187-193. PMID: 37694765, DOI: 10.1097/moh.0000000000000786.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHematopoietic stem cell transplantationDonor/recipient chimerismStem cell transplantationSickle cell diseasePost-HCTRecipient chimerismDonor chimerismCell transplantationCell diseaseDisease controlDonor-derived erythropoiesisHCT conditioning regimensMixed donor chimerismSerial chimerism analysesRecent clinical trialsDonor erythropoiesisConditioning regimensHigh morbidityCurative interventionsClinical trialsSuccessful engraftmentSCD manifestationsMyeloid cellsHb S traitChimerism analysisCan defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation?
Shah N, Shenoy S. Can defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation? The Lancet Haematology 2023, 10: e309-e311. PMID: 37001535, DOI: 10.1016/s2352-3026(23)00065-0.Peer-Reviewed Original ResearchCitationsAltmetric378 Main Reasons for Performing Hematopoietic Cell Transplantation in Patients with Sickle Cell Disease: Evolution over the Last Three Decades
Flagg A, He Z, Deng Y, Hamidi R, Shah N, Krishnamurti L. 378 Main Reasons for Performing Hematopoietic Cell Transplantation in Patients with Sickle Cell Disease: Evolution over the Last Three Decades. Transplantation And Cellular Therapy 2023, 29: s285-s286. DOI: 10.1016/s2666-6367(23)00447-5.Peer-Reviewed Original ResearchCitations
News & Links
News
- July 26, 2023
2022-23 Department of Pediatrics Faculty Awards
- May 04, 2023
42 Yale Pediatricians Recognized by Connecticut Magazine's 2023 “Top Doctors” List
- May 01, 2023
Connecticut Magazine’s 2023 “Top Doctors” issue recognizes 81 Smilow Cancer Hospital and Yale Cancer Center physicians
- October 12, 2022
Pediatric Bone Marrow Transplant Reunion
Get In Touch
Contacts
Email
Academic Office Number
Appointment Number
Mailing Address
Pediatric Hematology & Oncology
333 Cedar Street, LMP 2073
New Haven, CT 06510
United States